| Contributors |
|
xi | |
| Preface |
|
xv | |
|
1 Vasotocin and the origins of the vasopressin/oxytocin receptor gene family |
|
|
1 | (28) |
|
|
|
|
|
|
|
2 | (4) |
|
2 Emergence of the second ligand and derivation of the oxytocin receptor |
|
|
6 | (10) |
|
3 Evolution of the V2A receptor and cAMP signaling |
|
|
16 | (3) |
|
4 Promoter region regulatory elements and evolution of expression |
|
|
19 | (2) |
|
5 Conclusions and future directions |
|
|
21 | (2) |
|
|
|
23 | (1) |
|
|
|
24 | (5) |
|
2 Oxytocin/vasopressin-like neuropeptide signaling in insects |
|
|
29 | (26) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30 | (2) |
|
2 OT/VP-like signaling in beetles |
|
|
32 | (3) |
|
3 OT/VP-like signaling in locusts |
|
|
35 | (4) |
|
4 OT/VP-like signaling in ants |
|
|
39 | (3) |
|
5 Mining of ligand and receptor genes in other insects |
|
|
42 | (3) |
|
6 Possible applications of insect inotocin ligands in pharmacology |
|
|
45 | (3) |
|
|
|
48 | (1) |
|
|
|
48 | (7) |
|
3 Amyloid-like aggregation of provasopressin |
|
|
55 | (24) |
|
|
|
|
|
Cristina Prescianotto Baschong |
|
|
|
|
1 Biosynthesis and secretion of vasopressin |
|
|
56 | (4) |
|
2 Autosomal dominant neurohypophyseal diabetes insipidus (ADNDI) caused by amyloid-like provasopressin aggregation in the ER |
|
|
60 | (4) |
|
3 Granule sorting by functional amyloid aggregation in the TGN |
|
|
64 | (1) |
|
4 Sequence elements mediating ER aggregation and granule sorting |
|
|
65 | (5) |
|
5 Provasopressin is a physiological substrate of ERAD |
|
|
70 | (4) |
|
|
|
74 | (1) |
|
|
|
74 | (5) |
|
4 V2 vasopressin receptor mutations |
|
|
79 | (22) |
|
|
|
|
|
|
|
|
|
1 Short introduction: V2 receptor and its physiological role in the kidney |
|
|
80 | (1) |
|
2 X-linked congenital nephrogenic diabetes insipidus (NDI) |
|
|
80 | (2) |
|
3 Loss-of-function mutations of V2R that cause NDI |
|
|
82 | (10) |
|
4 Gain-of-function mutations causing nephrogenic syndrome of inappropriate antidiuresis (NSIAD) |
|
|
92 | (2) |
|
|
|
94 | (1) |
|
|
|
94 | (7) |
|
5 Vasopressin inactivation: Role of insulin-regulated aminopeptidase |
|
|
101 | (28) |
|
|
|
Estifanos N. Habtemichael |
|
|
|
|
1 Introduction: Antidiuretic activity is regulated enzymatically by vasopressin inactivation |
|
|
102 | (2) |
|
2 Discovery and function of placental leucine aminopeptidase |
|
|
104 | (2) |
|
3 Discovery and characterization of insulin regulated aminopeptidase (IRAP) |
|
|
106 | (7) |
|
4 TUG mediates coordinated regulation of water and glucose homeostasis |
|
|
113 | (2) |
|
5 Implications of vasopressin degradation: Copeptin and the metabolic syndrome |
|
|
115 | (3) |
|
|
|
118 | (1) |
|
|
|
119 | (1) |
|
|
|
119 | (10) |
|
6 Molecular aspects of aquaporins |
|
|
129 | (54) |
|
|
|
|
|
|
|
1 Discovery of the first aquaporin |
|
|
130 | (1) |
|
2 Classification and isoforms of mammalian aquaporins |
|
|
131 | (6) |
|
3 Structural characterization of mammalian aquaporins |
|
|
137 | (2) |
|
4 Protein modification of AQP2 |
|
|
139 | (11) |
|
5 Molecular machinery of AQP2 trafficking |
|
|
150 | (6) |
|
6 AQP2 protein abundance by vasopressin and others |
|
|
156 | (3) |
|
7 Pathophysiology of vasopressin-regulated AQP2 |
|
|
159 | (4) |
|
|
|
163 | (1) |
|
|
|
163 | (20) |
|
7 The vasotocinergic system and its role in the regulation of stress in birds |
|
|
183 | (34) |
|
|
|
|
|
|
|
|
|
184 | (1) |
|
2 Anatomy of the avian HPA axis, with emphasis on arginine vasotocin (AVT) |
|
|
185 | (9) |
|
3 Roles of AVT and CRH in regulating blood concentration of corticosterone in birds |
|
|
194 | (5) |
|
4 Receptors associated with stress within the anterior pituitary and vasotocin antagonists specific for the avian Via and V1bRs |
|
|
199 | (8) |
|
5 Conclusions and future directions |
|
|
207 | (1) |
|
|
|
207 | (1) |
|
|
|
208 | (8) |
|
|
|
216 | (1) |
|
8 Vasopressin actions in the kidney renin angiotensin system and its role in hypertension and renal disease |
|
|
217 | (22) |
|
|
|
|
|
|
|
|
|
|
|
218 | (1) |
|
2 Vasopressin and its receptors in the kidney |
|
|
219 | (2) |
|
3 Structural characterization of vasopressin receptors |
|
|
221 | (5) |
|
4 Vasopressin actions in the kidney renin angiotensin system |
|
|
226 | (1) |
|
5 Vasopressin in hypertension |
|
|
227 | (1) |
|
6 Vasopressin and kidney disease |
|
|
228 | (4) |
|
7 Conclusions and future directions |
|
|
232 | (1) |
|
|
|
233 | (6) |
|
9 Vasopressin receptor subtypes and renal sodium transport |
|
|
239 | (20) |
|
|
|
|
|
1 Phenomenology of vasopressin-induced natriuresis |
|
|
240 | (1) |
|
|
|
240 | (1) |
|
3 Vasopressin and receptors in the kidney |
|
|
241 | (5) |
|
|
|
246 | (3) |
|
5 Natriuretic effect of vasopressin |
|
|
249 | (3) |
|
|
|
252 | (1) |
|
|
|
252 | (1) |
|
|
|
253 | (6) |
|
10 Development and therapeutic potential of vasopressin synthetic analog [ V4Q5]dDAVP as a novel anticancer agent |
|
|
259 | (32) |
|
|
|
|
|
|
|
|
|
|
|
260 | (4) |
|
2 Design of novel AVP synthetic analogs as anticancer agents |
|
|
264 | (5) |
|
3 [ V4Q5]dDAVP as a second generation AVP analog with enhanced biological activity |
|
|
269 | (11) |
|
4 Conclusions and future perspectives |
|
|
280 | (2) |
|
|
|
282 | (1) |
|
|
|
282 | (9) |
|
11 Vasopressin and vasopressin receptors in brain edema |
|
|
291 | |
|
|
|
|
|
|
|
1 Vasopressin and vasopressin receptors |
|
|
292 | (3) |
|
|
|
295 | (1) |
|
3 Water diffusion and vasopressin in brain edema |
|
|
296 | (2) |
|
4 Injury-induced brain edema and vasopressin |
|
|
298 | (2) |
|
5 Subarachnoid hemorrhage (SAH)-induced brain edema and vasopressin |
|
|
300 | (1) |
|
6 Kidneys, brain edema and vasopressin |
|
|
301 | (1) |
|
7 Inflammation in brain edema and vasopressin |
|
|
302 | (1) |
|
8 Liver disease-caused brain edema and vasopressin |
|
|
303 | (1) |
|
|
|
303 | (1) |
|
|
|
304 | (1) |
|
|
|
304 | |
